The IBD SmartSelect Composite Rating for Phibro Animal Health increased from 87 to 96 Friday.
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The best stocks tend to have a 95 or better grade as they begin to launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Phibro Animal Health is now out of buy range after breaking out from an 18.70 buy point in a flat base. Be aware that it is a thinly traded stock, with average daily dollar volume under $8 million.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock has an 85 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 85% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors over the last 13 weeks.
The company reported a 150% increase in earnings for Q1. That marks four straight quarters of rising EPS performance. Top line growth increased 13%, up from 7% in the prior report. That marks one quarter of accelerating revenue increases.
Phibro Animal Health holds the No. 1 rank among its peers in the Medical-Ethical Drugs industry group. Bristol Myers Squibb and Protagonist Therapeutics are also among the group's highest-rated stocks.
